Phase 1 dose-escalation, safety / tolerability and preliminary efficacy study of intratumoral and subcutaneous administration of GEN0101 in patients with recurrence of castration resistant prostate cancer
Latest Information Update: 06 Nov 2021
At a glance
Most Recent Events
- 01 May 2020 Results published in the Cancer Science
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 18 Oct 2017 Status changed from recruiting to completed.